The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia

Nada Abu-Shraie, Afaf Al-Sheikh, Ibtisam Alharbi, Layla Alanizy, Mohammed Alshraim, Sahal Khoshhal, Sarah AlSalman, Ali Alrumaih, Ahmad Fasseeh, Baher Elezbawy, Nada Abaza, Amr Semida, Marina George, Shireen Amin, Yousef Binamer

Open source

DOI: 10.2147/ceor.s604093
Published: 2026-06
Container: ClinicoEconomics and Outcomes Research
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2147/ceor.s604093,
  title = {The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia},
  author = {Nada Abu-Shraie and Afaf Al-Sheikh and Ibtisam Alharbi and Layla Alanizy and Mohammed Alshraim and Sahal Khoshhal and Sarah AlSalman and Ali Alrumaih and Ahmad Fasseeh and Baher Elezbawy and Nada Abaza and Amr Semida and Marina George and Shireen Amin and Yousef Binamer},
  year = {2026},
  journal = {ClinicoEconomics and Outcomes Research},
  doi = {10.2147/ceor.s604093},
  url = {https://doi.org/10.2147/ceor.s604093}
}

RIS

TY  - JOUR
TI  - The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia
AU  - Nada Abu-Shraie
AU  - Afaf Al-Sheikh
AU  - Ibtisam Alharbi
AU  - Layla Alanizy
AU  - Mohammed Alshraim
AU  - Sahal Khoshhal
AU  - Sarah AlSalman
AU  - Ali Alrumaih
AU  - Ahmad Fasseeh
AU  - Baher Elezbawy
AU  - Nada Abaza
AU  - Amr Semida
AU  - Marina George
AU  - Shireen Amin
AU  - Yousef Binamer
PY  - 2026
JO  - ClinicoEconomics and Outcomes Research
DO  - 10.2147/ceor.s604093
UR  - https://doi.org/10.2147/ceor.s604093
ER  -

APA

Abu-Shraie, N., Al-Sheikh, A., Alharbi, I., Alanizy, L., Alshraim, M., Khoshhal, S., AlSalman, S., Alrumaih, A., Fasseeh, A., Elezbawy, B., Abaza, N., Semida, A., George, M., Amin, S., & Binamer, Y. (2026). The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia. ClinicoEconomics and Outcomes Research. https://doi.org/10.2147/ceor.s604093

Source records

crossref · retrieved 2026-09-26T10:25:46.356Z